UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)Business Wire • 12/19/22
UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder CancerBusiness Wire • 12/02/22
UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial CancerBusiness Wire • 12/02/22
UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx ConferenceBusiness Wire • 11/21/22
UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial CarcinomaBusiness Wire • 11/14/22
UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate DevelopmentsBusiness Wire • 11/10/22
UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of DirectorsBusiness Wire • 11/09/22
UroGen Pharma to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022Business Wire • 11/03/22
Urogen Pharma (URGN) Moves 10.3% Higher: Will This Strength Last?Zacks Investment Research • 10/12/22
UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder CancersBusiness Wire • 10/11/22
FDA Authorizes an Extension of the In-Use Period for UroGen Pharma's JELMYTO® Admixture to 96 Hours Following ReconstitutionBusiness Wire • 09/28/22
UroGen Announces the Appointment of Dr. Leana S. Wen to the UroGen Pharma Board of DirectorsBusiness Wire • 09/12/22
Urogen Pharma Ltd (URGN) CEO Elizabeth Barrett on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/11/22
UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate DevelopmentsBusiness Wire • 08/11/22
UroGen Pharma to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022Business Wire • 07/27/22
UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO®, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial CancerBusiness Wire • 05/16/22
UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual MeetingBusiness Wire • 05/13/22
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/10/22
UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate DevelopmentsBusiness Wire • 05/10/22